US Purpura treatment Market

ID: MRFR/Pharma/16773-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
US Purpura Treatment Market Research Report By Treatment Type (Corticosteroids, Intravenous Immunoglobulin, Platelet Transfusion, Desmopressin, Immunosuppressants), By Patient Type (Pediatric, Adult, Geriatric), By Disease Type (Immune Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Apparent Benign Purpura) and By Administration Route (Intravenous, Oral, Subcutaneous) - Growth & Industry Forecast 2025 To 2035
US Purpura treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.09%
2024 Market Size$ 278.56 Million
2025 Market Size$ 298.32 Million
2035 Market Size$ 592.06 Million
Key Players
Bristol-Myers Squibb
Amgen
Roche
Novartis
Pfizer
Sanofi
Trends
  • Rise of Personalized Medicine
  • Advancements in Biologics
  • Telemedicine Integration
Opportunities
  • Rising Healthcare Expenditure
  • Growing Awareness and Education
  • Advancements in Treatment Modalities
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Treatment Type (USD Million)
      1. 4.1.1 Corticosteroids
      2. 4.1.2 Intravenous Immunoglobulin
      3. 4.1.3 Platelet Transfusion
      4. 4.1.4 Desmopressin
      5. 4.1.5 Immunosuppressants
    2. 4.2 Chemicals and Materials, BY Patient Type (USD Million)
      1. 4.2.1 Pediatric
      2. 4.2.2 Adult
      3. 4.2.3 Geriatric
    3. 4.3 Chemicals and Materials, BY Disease Type (USD Million)
      1. 4.3.1 Immune Thrombocytopenic Purpura
      2. 4.3.2 Thrombotic Thrombocytopenic Purpura
      3. 4.3.3 Apparent Benign Purpura
    4. 4.4 Chemicals and Materials, BY Administration Route (USD Million)
      1. 4.4.1 Intravenous
      2. 4.4.2 Oral
      3. 4.4.3 Subcutaneous
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Amgen (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Sanofi (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Takeda (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 GSK (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY PATIENT TYPE
    4. 6.4 US MARKET ANALYSIS BY DISEASE TYPE
    5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY PATIENT TYPE, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY DISEASE TYPE, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY PATIENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY DISEASE TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Purpura treatment Market Segmentation

US Purpura treatment Market By Treatment Type (USD Million, 2025-2035)

  • Corticosteroids
  • Intravenous Immunoglobulin
  • Platelet Transfusion
  • Desmopressin
  • Immunosuppressants

US Purpura treatment Market By Patient Type (USD Million, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

US Purpura treatment Market By Disease Type (USD Million, 2025-2035)

  • Immune Thrombocytopenic Purpura
  • Thrombotic Thrombocytopenic Purpura
  • Apparent Benign Purpura

US Purpura treatment Market By Administration Route (USD Million, 2025-2035)

  • Intravenous
  • Oral
  • Subcutaneous

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.